One of the next steps is to determine if our nanobodies, when delivered to cells, will block CNNM binding to PRL-3 and can be used as an inhibitor on their own or coupled to a chemotherapy or cytotoxic protein to prevent the growth and spread of cancer cells. Here, PTP4A3 is linked to cancer.